Description: Advanced Solid Tumors: ABBV-400 as Monotherapy-A Global First-in-Human Study Mechanism of Action: Antibody drug conjugate targeting c-MET with a topoisomerase inhibitor payload Target Patient Population: All solid tumors Study Design: Study drug is administered IV every 3 weeks For more information on this trial, read its profile on clinicaltrials.gov here.
C-1400-01 (AGEN1777) (Agenus, Inc.) Description: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors Mechanism of Action: bispecific antibody targeting TIGIT and CD96 (to enhance T and NK cell activation) Target Population: All solid tumors. To be given as single agent or in
ALKS 4230-003 (Alkermes Inc. ) Description: Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3) Mechanism of Action: IL2 receptor agonist Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors
ALPN-202 – NEON-2 (Alpine Immune Sciences) Description: An open-Label Study of ALPN-202 Combined With PD-1 Inhibition In Subjects With Advanced Malignancies (NEON-2) Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator in combination with Pembrolizumab. Target Patient Population:. All solid tumors Study Design: Study drug is administered IV every 1 or 3 weeks
A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) PI: Amy VanderWoude Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint
BBI-20201001 (Bolt) Description: Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors Mechanism of Action: Immune stimulating antibody drug conjugate – trastuzumab like antibody conjugated to a TLR7/8 payload. Currently combination with Pembrolizumab. Target Patient Population: Advanced solid tumor patients with IHC
CA115-001 (Bristol Myers Squibb) Description: Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small cell Lung Cancer Mechanism of Action: Bispecific antibody TIGIT and CD96 Target Patient Population: Starting with dose escalation in advanced solid tumors with specific cohorts in combination with Nivolumab
CPI-0209-01 (Constellation) Description: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors Mechanism of Action: EZH2 Inhibitor Target Patient Population: In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial. Study Design: Drug is given orally daily.
CLN-619-001 (Cullinan) Description: A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Mechanism of Action: Monoclonal antibody that specifically binds the NKG2D ligands MICA and MICB and prevents their proteolytic release from the surface